Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Trial of an Oral Formulation Containing a Mucoadhesive Polymer Hydrogel Vehicle (MucoLox®) to Mitigate Mucositis Symptoms in Head/Neck Cancer Patients Receiving Radiation ± Chemotherapy

NCT03461354 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.

NCT NCT03461354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03461354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Trial of an Oral Formulation Containing a Mucoadhesive Polymer Hydrogel Vehicle (MucoLox®) to Mitigate Mucositis Symptoms in Head/Neck Cancer Patients Receiving Radiation ± Chemotherapy
Lead sponsor
Wake Forest University Health Sciences
Phase
Not applicable
Overall status
Terminated
Start date
April 9, 2018
Completion date
April 1, 2024
Enrollment
49 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, mucositis oral